Get started
Unity Biotechnology, Inc.Unity Biotechnology, Inc.Unity Biotechnology, Inc.

Unity Biotechnology, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

UBX chart


Full chart

UBX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪16.69 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.5442 USD
Net income (FY)
‪−25.99 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪15.24 M‬
Beta (1Y)
1.18

Employees


Employees (FY)
16
Change (1Y)
−3 −15.79%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.62 M‬ USD

About Unity Biotechnology, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Anirvan Ghosh
Website
unitybiotechnology.com
Headquarters
South San Francisco
Founded
2009
FIGI
BBG00F412FG6
Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

UBX news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as UBX.

Frequently Asked Questions


The current price of UBX is 0.9700 USD — it has decreased by −1.98% in the past 24 hours. Watch Unity Biotechnology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Unity Biotechnology, Inc. stocks are traded under the ticker UBX.
UBX stock has risen by 11.11% compared to the previous week, the month change is a −45.81% fall, over the last year Unity Biotechnology, Inc. has showed a −35.76% decrease.
We've gathered analysts' opinions on Unity Biotechnology, Inc. future price: according to them, UBX price has a max estimate of 8.00 USD and a min estimate of 4.00 USD. Watch UBX chart and read a more detailed Unity Biotechnology, Inc. stock forecast: see what analysts think of Unity Biotechnology, Inc. and suggest that you do with its stocks.
UBX reached its all-time high on Sep 17, 2018 with the price of 245.6000 USD, and its all-time low was 0.8531 USD and was reached on Apr 8, 2025. View more price dynamics on UBX chart.
See other stocks reaching their highest and lowest prices.
UBX stock is 11.23% volatile and has beta coefficient of 1.18. Track Unity Biotechnology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Unity Biotechnology, Inc. there?
Today Unity Biotechnology, Inc. has the market capitalization of ‪16.36 M‬, it has decreased by −3.65% over the last week.
Yes, you can track Unity Biotechnology, Inc. financials in yearly and quarterly reports right on TradingView.
Unity Biotechnology, Inc. is going to release the next earnings report on May 13, 2025. Keep track of upcoming events with our Earnings Calendar.
UBX earnings for the last quarter are −0.50 USD per share, whereas the estimation was −0.39 USD resulting in a −29.50% surprise. The estimated earnings for the next quarter are −0.35 USD per share. See more details about Unity Biotechnology, Inc. earnings.
Unity Biotechnology, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
UBX net income for the last quarter is ‪−8.44 M‬ USD, while the quarter before that showed ‪−6.48 M‬ USD of net income which accounts for −30.23% change. Track more Unity Biotechnology, Inc. financial stats to get the full picture.
No, UBX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 16 employees. See our rating of the largest employees — is Unity Biotechnology, Inc. on this list?
Like other stocks, UBX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Unity Biotechnology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Unity Biotechnology, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Unity Biotechnology, Inc. stock shows the sell signal. See more of Unity Biotechnology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.